229 related articles for article (PubMed ID: 33775711)
1. Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
Lin CY; Huang KY; Lin YC; Yang SC; Chung WC; Chang YL; Shih JY; Ho CC; Lin CA; Shih CC; Chang YH; Kao SH; Yang PC
Cancer Lett; 2021 Jun; 508():76-91. PubMed ID: 33775711
[TBL] [Abstract][Full Text] [Related]
2. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
[TBL] [Abstract][Full Text] [Related]
3. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
[TBL] [Abstract][Full Text] [Related]
4. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
[TBL] [Abstract][Full Text] [Related]
5. Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.
Huang KY; Wang TH; Chen CC; Leu YL; Li HJ; Jhong CL; Chen CY
Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572484
[TBL] [Abstract][Full Text] [Related]
6. Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.
Wang X; Zhou L; Yin JC; Wu X; Shao YW; Gao B
J Thorac Oncol; 2019 May; 14(5):e85-e88. PubMed ID: 30711650
[No Abstract] [Full Text] [Related]
7. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR
Fang H; Wu Y; Xiao Q; He D; Zhou T; Liu W; Yang CH; Xie Y
Bioorg Med Chem Lett; 2022 Sep; 72():128729. PubMed ID: 35413415
[TBL] [Abstract][Full Text] [Related]
9. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
[TBL] [Abstract][Full Text] [Related]
10. Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review.
Liu J; Lei H; Zhang D; Zhang N
Anticancer Drugs; 2024 Jul; 35(6):569-575. PubMed ID: 38527281
[TBL] [Abstract][Full Text] [Related]
11. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
16. Reprogramming Tumor-Associated Macrophages To Reverse EGFR
Peng H; Chen B; Huang W; Tang Y; Jiang Y; Zhang W; Huang Y
Nano Lett; 2017 Dec; 17(12):7684-7690. PubMed ID: 29160717
[TBL] [Abstract][Full Text] [Related]
17. Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
Wang Y; Liu Q; Chen H; You J; Peng B; Cao F; Zhang X; Chen Q; Uzan G; Xu L; Zhang D
Anticancer Drugs; 2018 Sep; 29(8):748-755. PubMed ID: 29927769
[TBL] [Abstract][Full Text] [Related]
18. Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Lee C; Kim M; Kim DW; Kim TM; Kim S; Im SW; Jeon YK; Keam B; Ku JL; Heo DS
Cancer Res Treat; 2022 Jan; 54(1):140-149. PubMed ID: 33940786
[TBL] [Abstract][Full Text] [Related]
19. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
20. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]